Hims & Hers—the virtual care platform with about 2.5 million subscribers—will now offer laboratory testing through Quest Diagnostics. Customers will have access to more than 120 biomarker tests across ...

Wall Street expects another quarter of double-digit topline growth with EPS of $0.10 on $579 million revenue. The call centered around Hims & Hers’ push beyond treatment into proactive and ...

Hims & Hers Health said it is now providing menopause care, marking the company’s latest push into hormone-replacement therapies. The telehealth company sees the new offering as a major opportunity to ...

Hims & Hers Health HIMS-5.13%decrease; red down pointing triangle said it is now providing menopause care, marking the company’s latest push into hormone-replacement therapies. The telehealth company ...

If you purchase an independently reviewed product or service through a link on our website, SheKnows may receive an affiliate commission. If you’re considering using one of these new digital platforms ...

Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of weight-loss drugs. By Christina Jewett Rebecca Robbins and Dani Blum The ...

Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short ...

Hims & Hers Health, Inc. (NYSE:HIMS) has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally. Hims & Hers stock has ...

LOS ANGELES — Hims & Hers, the high-flying online health company that rapidly ascended from a buzzy startup selling Viagra to a multibillion-dollar business with a Super Bowl ad, had a hard month. The ...

Hims & Hers is disrupting the healthcare industry, testing the limits of regulation to make it easier for people to buy popular drugs at lower prices online. This week, the telehealth company faced ...

Just a couple of months after launching a partnership with direct-to-consumer telehealth company Hims & Hers, Novo Nordisk is terminating the collaboration, the company announced on Monday. The drug ...